Meeting
2023 ASCO Annual Meeting
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.
Authors
Hamzah Abu-Sbeih
The Ohio State University, Columbus, OH
Hamzah Abu-Sbeih , Meghana Moodabagil , Jing Peng , Jianing Ma , Robert Easterling , Matthew Viveiros , Mingjia Li , Austin Secor , Evelyn Goodyear , Kari Lynn Kendra , Gregory Alan Otterson , Carolyn J Presley , Edwin Donnelly , Alexa Simon Meara , Dwight Hall Owen , Kevin Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2658)
DOI
10.1200/JCO.2023.41.16_suppl.2658
Abstract #
2658
Poster Bd #
500
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The impact of pembrolizumab on patients with pre-existing autoimmune diseases.
First Author: Noor Bazerbashi
Poster
2021 ASCO Annual Meeting
Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy.
First Author: Kate E Lee
First Author: Rebecca Jeun
Poster
2021 ASCO Annual Meeting
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
First Author: Hamzah Abu-Sbeih